QP-Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for Melanoma (Adults)
Details
- Buyer
- NHS England
- Published
- 8 September 2025
- Submission
- 13 October 2025
- Source
- uk:atamis:dhsc
Tender description
The Provider Selection Regime (PSR) Competitive Process is being utilised to facilitate the accreditation of suitably qualified providers to establish that they meet the requirements to deliver the Service. For the avoidance of doubt, the services covered in this Competitive Process are not subject to a legal right to patient choice. The key objective of the Competitive Process is to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, initially for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots, to serve the population of England. There is no restriction on the number of sites that will be commissioned, however providers may only bid for one Lot.
Timeline
- Completed: Tender published8 September 2025Current notice
- Completed: Submission date13 October 2025
About the buyer
NHS England runs the NHS in England, and buys as a central healthcare organisation with its own team of procurement professionals. Much of this procurement flows through framework agreements and the Crown Commercial Service. Seven regional teams support the commissioning of healthcare services across the country. The central commercial function that develops procurement strategy for the whole NHS sits here.
Clinical services are commissioned directly or through the Provider Selection Regime.
Over the past 5 years, most of NHS England's contract awards have been in education and training, health and social work, and IT services.
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
Related topics
Topics related to QP-Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for Melanoma (Adults), ranked by notice volume.
- 11,505£1.0tn
- 32,494£2.0tn
Related buyers
Buyers similar to NHS England.
- 512£249.4m
- 434£15.3bn
- 414£111.6m
- 390£652.7m
- 328£25.1bn
- 295£1.6bn
- 293£1.3bn
- 283£3.1bn
- 154£121.9m
- 148£1.0bn
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.